ADORA2A and Parkinson disease: The adenosine modulation system has emerged in recent years as a candidate target to alleviate the burden of PD, leading to the FDA approval of adenosine A2A receptor (A2AR) antagonists as the first nondopaminergic therapy for PD [20].